Letrozole Pretreatment With Misoprostol Induction of Abortion In First-Trimester Missed Miscarriage
NCT ID: NCT04215835
Last Updated: 2020-01-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
200 participants
INTERVENTIONAL
2020-01-05
2020-04-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Letrozole Pretreatment With Misoprostol Versus Misoprostol Alone in Missed Abortion
NCT04217265
Letrozole Pretreatment With Misoprostol fInduction of Abortion In First-Trimester Missed Miscarriage
NCT03628625
Use of Letrozole Pretreatment With Misoprostol for First-Trimester Medical Abortion
NCT02401425
Effectiveness of Pretreatment Letrozole Versus Misoprostol Alone in Missed Abortion
NCT04194658
Letrozole Pretreatment With Misoprostol for Second-Trimester Medical Abortion
NCT02405156
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
study group
3 tablets of Letrozole 2.5 mg will be given as single daily dose, 7.5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum two doses.
letrozole then misoprostol
Drug: Letrozole 2.5mg total dose 7.5 mg per day for 3 days
Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion
control group
three tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum two doses
placebo then misoprostol
Drug: Placebo placebo for 3 days
Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
letrozole then misoprostol
Drug: Letrozole 2.5mg total dose 7.5 mg per day for 3 days
Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion
placebo then misoprostol
Drug: Placebo placebo for 3 days
Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hemoglobin \>10 g/dL.
* BMI between 18.5 kg/m2 and 25 kg/m2.
* Missed abortion.
* previous one or more cesarean delivaries
Exclusion Criteria
* Fibroid uterus.
* Uterine anomalies.
* Coagulopathy.
* Medical disorder that contraindicate induction of abortion (e.g. heart failure).
* Previous attempts for induction of abortion in the current pregnancy.
* Allergy to misoprostol or letrozole.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Samy aly ashour
assistant professor obstetrics and gynecology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AHMED SAMY
Role: PRINCIPAL_INVESTIGATOR
Cairo University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
letrozole pretreatment
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.